Making high-affinity T-cell receptors: a new class of targeted therapeutics

IDrugs. 2006 Aug;9(8):554-9.


The last two decades have seen the development of an expanding array of monoclonal antibodies, which are proving to be effective treatments for both cancer and autoimmune disease. A related protein, the human T-cell receptor (TCR), is able to access a new range of targets for which antibodies are unsuitable, and is being developed as a new class of protein therapeutics. Similar to antibodies, TCRs have a specific target and therefore a limited potential for side effects; however, a possible drawback with these receptors is that their natural affinity is low. This problem has recently been overcome using phage display to increase TCR affinity up to a million-fold.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Humans
  • Peptide Library
  • Receptors, Antigen, T-Cell / chemistry*
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / immunology


  • Antibodies, Monoclonal
  • Peptide Library
  • Receptors, Antigen, T-Cell